Antibacterial Use and Resistance Patterns in Psychiatric Hospitals During the COVID-19 Epidemic

Study Background and Research Question

The COVID-19 pandemic has placed unprecedented strain on healthcare systems, with psychiatric hospitals facing unique challenges due to their patient demographics and facility design. Psychiatric inpatients often have compromised immune systems, limited self-care capacity, and reside in closed environments that facilitate both viral and bacterial transmission. The rise in bacterial co-infections among COVID-19 patients necessitates judicious antibacterial drug use, yet overuse or misuse can accelerate the development of antibiotic resistance. The reference study sought to clarify how antibacterial drugs were used in a large psychiatric hospital during the 2022 epidemic and to profile the patterns of bacterial resistance that emerged in this high-risk context.

Key Innovation from the Reference Study

This research is among the first to systematically evaluate antibiotic utilization and bacterial resistance within psychiatric hospitals during a pandemic period. Leveraging both the hospital’s information system and the National Antibacterial Drug Clinical Application Monitoring Network, the authors provided granularity not only in usage metrics but also in resistance trends among both Gram-negative and Gram-positive bacteria. Notably, the study contextualizes findings against provincial and national benchmarks, revealing that—despite the heightened risk environment—antibiotic use rates and costs at the studied psychiatric hospital remained below regional and national averages, while maintaining a high rate of microbiological submission for antibiotic prescribing (see study).

Methods and Experimental Design Insights

The study adopted a retrospective design, extracting 2022 data from electronic medical records and the national surveillance platform. Key metrics included:

• Antibiotic use rate and intensity (AUD)
• Combined medication rate
• Cumulative defined daily doses (DDDs)
• Antibiotic cost percentage of total drug expenses
• Rate of microbiological submission for antibiotic use
• Pathogen identification and drug susceptibility profiles

The authors focused on the most commonly used antibiotic classes: third-generation cephalosporins, penicillins, and quinolones, with cefodizime, amoxicillin, and piperacillin–tazobactam being the top agents by DDDs.

Core Findings and Why They Matter

Several findings stand out:

• Low antibiotic usage rates: The psychiatric hospital reported a 5.0% antibiotic use rate, with antibiotic costs representing just 3.95% of total drug expenses—significantly below both Jiangsu Province and national averages.
• High microbiological stewardship: The rate of microbiological submission for antibacterial drug use reached 77.78%, exceeding regional and national practices. This suggests a strong institutional emphasis on targeted, evidence-based therapy.
• Resistance trends: Gram-negative pathogens showed pronounced resistance to penicillins, cephalosporins, and quinolones (notably ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, ciprofloxacin). Gram-positive bacteria resisted penicillins, macrolides, and quinolones (notably penicillin, benzylpenicillin, erythromycin, levofloxacin, ciprofloxacin).
• Implications: The study highlights the persistent risk of resistance even when overall antibiotic use is controlled, underscoring the importance of ongoing resistance surveillance and stewardship programs to optimize clinical outcomes and prevent the emergence and spread of multi-drug-resistant organisms (reference).

These findings provide a nuanced perspective: while judicious use and microbiological guidance can mitigate overuse, the closed environment of psychiatric facilities and predisposing patient factors sustain a high baseline risk for resistance development.

Comparison with Existing Internal Articles

While the reference study focuses on antibacterial stewardship in the psychiatric context, parallels can be drawn to research on anti-inflammatory agents and their roles in infection and immunity. For instance, internal benchmarking of Gamma-linolenic acid (GLA) demonstrates its utility as a weak Leukotriene B4 receptor antagonist with anti-inflammatory and cytoprotective effects. Such mechanisms are relevant in managing inflammatory responses secondary to infection or antibiotic treatment, as discussed in the context of atopic dermatitis treatment and apoptosis assay optimization. Relatedly, the article "Gamma-linolenic Acid: Optimizing Anti-Inflammatory Research Workflows" provides actionable strategies for integrating GLA into translational workflows—an approach that could inform adjunctive research alongside antibacterial stewardship.

Protocol Parameters

• Microbiological submission rate: Target >75% when prescribing new antibiotics to psychiatric inpatients, as high rates are associated with more rational antibiotic use.
• Antibiotic selection: Base empirical therapy on local resistance data, especially for Gram-negative and Gram-positive organisms commonly encountered in psychiatric settings.
• Antibiotic use intensity (AUD): Monitor monthly, aiming to keep levels below regional and national benchmarks where possible.
• Adjunctive anti-inflammatory research: When investigating immune modulation or inflammation secondary to infection, consider integrating omega-6 polyunsaturated fatty acids such as GLA, as supported by literature on its weak LTB4 receptor antagonist activity and its application in apoptosis assays.

Limitations and Transferability

Although the study provides valuable insights, it is limited by its single-center, retrospective design, which may not capture the full heterogeneity of psychiatric hospitals nationwide or internationally. Differences in local prescribing culture, infection control protocols, and patient demographics may influence transferability. Moreover, the impact of anti-inflammatory adjuncts such as GLA on infection outcomes was not directly assessed in this cohort, representing an area for future translational research.

Why this cross-domain matters, maturity, and limitations

The intersection between antibacterial stewardship and anti-inflammatory research is of growing interest, particularly as both bacterial infection and the host inflammatory response shape patient outcomes in psychiatric and general hospital settings. Maturity in this area is evolving, with supportive evidence for agents like GLA in modulating inflammation and apoptosis, but additional direct clinical research is required before routine clinical integration, especially in psychiatric populations.

Research Support Resources

To replicate or extend findings in anti-inflammatory research, researchers may utilize Gamma-linolenic acid (GLA) (SKU C5518) from APExBIO, a well-characterized omega-6 polyunsaturated fatty acid with documented weak antagonism at the leukotriene B4 receptor. This reagent supports robust workflow development in apoptosis assays, anti-inflammatory research, and related studies on immune modulation, as outlined in the internal articles above.